Sep 15, 2021 / 02:15PM GMT
David Neil Lebowitz - Morgan Stanley, Research Division - VP
Welcome once again to the 19th Annual Morgan Stanley Healthcare Conference. I'm one of the biotechnology analysts here. My name is David Lebowitz. Before we get started, let me jump into the requisite disclosures. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
And with that, I'm happy to introduce in the next session from Arcutis, CEO, Frank Watanabe; CFO, Scott Burrows; CCO, Ken Lock; and CMO, Patrick Burnett.
Questions and Answers:
David Neil Lebowitz - Morgan Stanley, Research Division - VPI guess if you could start out Arcutis is late-stage dermatology company. You have one drug that already produced Phase III results and other -- some other Phase III trials that are in the works. Could you talk about the top level vision